Phaseline

Companies › NanoEcho

NanoEcho: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NanoEcho Particle-1 (NEP-1, Ferumoxtran)
Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles - iron oxide contrast agent
CANXPhase 2Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06693375NanoEcho Particle-1 (NEP-1, Ferumoxtran)Phase 2Healthy VolunteersOncologyMay 2026

Targets

CANX (1)

Companies with the same targets

–

Companies built like this

Syncromune Galecto Biotech VSPharmTech BPGbio Shanghai AB PharmaTech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.